加载中
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
前收盘价
US$135.28
+US$0.81 · +0.60%
盘中时间采用ET。市场数据可能有所延迟。
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
日内区间
当前US$135.28
52周区间
当前US$135.28
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
84
深度低估
情绪
70
看涨
风险
60
风险偏高
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
日内区间
当前US$135.28
52周区间
当前US$135.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 27.08亿 USD | 20.72亿 USD | 16.97亿 USD | 13.05亿 USD | 10.99亿 USD |
| 销货成本 | 7.68亿 USD | 6.26亿 USD | 5.37亿 USD | 5亿 USD | 3.47亿 USD |
| 毛利 | 19.4亿 USD | 14.46亿 USD | 11.6亿 USD | 8.06亿 USD | 7.52亿 USD |
| 研究与开发 | 3.01亿 USD | 2.2亿 USD | 2.05亿 USD | 1.8亿 USD | 1.6亿 USD |
| 销售、一般及管理费用 | 11.65亿 USD | 9.17亿 USD | 7.35亿 USD | 5.88亿 USD | 4.66亿 USD |
| 营业费用 | 14.66亿 USD | 11.37亿 USD | 9.4亿 USD | 7.68亿 USD | 6.26亿 USD |
| 利息收入 | 3470万 USD | 3950万 USD | 2860万 USD | 930万 USD | 50万 USD |
| 利息支出 | 7970万 USD | 4270万 USD | 3620万 USD | 3600万 USD | 6170万 USD |
| 折旧和摊销 | 9040万 USD | 8080万 USD | 7280万 USD | 6320万 USD | 5740万 USD |
| 营业利润 | 4.74亿 USD | 3.09亿 USD | 2.2亿 USD | 3760万 USD | 1.26亿 USD |
| 净利润 | 2.47亿 USD | 4.18亿 USD | 2.06亿 USD | 460万 USD | 1680万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$182.35
上涨空间 34.79%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T180.46亿0.01%129.35万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI3.28亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO2.73亿0.02%1.8万亿 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB2.37亿0.13%1853亿 USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP1.93亿0.20%977.83亿 USD0.20%US$213.04+0.55%
Vanguard Morningstar Small-Cap Growth ETFVBK1.36亿0.30%447亿 USD0.05%US$344.74+1.22%
iShares Core S&P 500 ETFIVV1.24亿0.01%8964.4亿 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY1.14亿0.01%8172亿 USD0.09%US$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Small-Cap Growth ETFVBKiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
